Biotechnology company Immutep (ASX:IMM) said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.
The triple combination therapy, based on a preliminary analysis of 21 patients, showed "significant" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.
The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.
The EFTISARC-NEO study, led by the Maria Skłodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.
The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.
Immutep shares rose nearly 5% in afternoon trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。